Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, has closed a registered direct offering priced at-the-market under Nasdaq rules, raising $2.5 million through the sale of 6,130,000 shares at $0.41 per share. Concurrently, the company issued unregistered warrants for an additional 6,130,000 shares with the same exercise price, expiring five years from stockholder approval. The net proceeds will support working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, announced a $2.5 million registered direct offering. The company will issue approximately 6.13 million shares at $0.41 per share. Unregistered warrants for the same amount of shares will be issued in a concurrent private placement. The offering is expected to close on June 21, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Mustang plans to use the net proceeds for working capital and general corporate purposes.
Mustang Bio has announced positive efficacy and safety data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted autologous CAR-T therapy, for Waldenstrom macroglobulinemia (WM). The trial demonstrated a 90% overall response rate among heavily pretreated patients, with durable responses noted, including one patient in complete remission for 31 months.
Outpatient administration was feasible, and no grade 3 or 4 CRS or severe neurotoxicity was observed. These results were presented at the European Hematology Association 2024 Hybrid Congress. Mustang Bio is developing MB-106 in collaboration with Fred Hutch Cancer Center and aims to advance the program further, contingent on acquiring additional funding or strategic partnerships.
Mustang Bio, Inc. announced the closing of a public offering, generating approximately $4 million in gross proceeds from the sale of common stock and warrants. The Company plans to use the funds for working capital and general corporate purposes. If all warrants are cash-exercised, potential additional gross proceeds of $12 million can be realized. The offering was facilitated by H.C. Wainwright & Co., with the securities offered under a registration statement on Form S-1 filed with the SEC.
Mustang Bio, Inc. announced a public offering of 16,877,638 shares of common stock, along with warrants, at a combined price of $0.237 per share to raise approximately $4 million. The offering is expected to close on May 2, 2024, with H.C. Wainwright & Co. as the placement agent. The proceeds will be used for working capital and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
